. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Nanomedicine. 2015 Mar 17;11(5):1133–1140. doi: 10.1016/j.nano.2015.02.020

Table 3.

Pharmacokinetics in rabbits

PK of PLP after administration in its liposomal encapsulated or free form in rabbits
PLP	Single dose LN-PLP (mg/kg)		Single dose free PLP (mg/kg)
PLP	1	10	1	10
Clearance (mL hour^-1 kg^-1)	1.35	0.53	^*	5494
Terminal half –life (T½) (hours)	19.4	39.9	^*	0.06
C_max (μg/mL)	29.9	342.0	1.69	20.3

PK of the active metabolite PL after administration of PLP in liposomal encapsulated or its free form in rabbits
PL	Single dose LN-PLP (mg/kg)		Single dose free PLP (mg/kg)
PL	1	10	1	10

Clearance (mL hour^-1 kg^-1)	nc^*	nc^*	3831	2808
Terminal half –life (T½) (hours)	nc^*	nc^*	0.29	0.25
C_max (μg/mL)	1.84	12.1	0.54	9.56

Half-life and clearance rate for 1mg/kg free PLP could not be determined due to undetectable PLP plasma levels after the first time point (t=0.08 hours).

C_max, maximal concentration; LN, liposomal nanoparticle; PL, prednisolone (active metabolite); PLP, prednisolone phosphate (prodrug); T½; terminal half-live.

nc, not calculated because plasma concentrations result of indirect release;